Long-term treatment of bronchial asthma with pirbuterol aerosol.

Abstract

In an open study in which 25 male outpatients with chronic obstructive pulmonary disease received pirbuterol aerosol for up to 14 months bronchodilator efficacy was maintained throughout. There were no serious side effects, and laboratory abnormalities were of little clinical relevance. Sinus bradycardia was the most frequently observed ECG change.

• Authors: H M Beumer
• Journal: International journal of clinical pharmacology, therapy, and toxicology (Int J Clin Pharmacol Ther Toxicol) Vol. 21 Issue 4 Pg. 172-5 (Apr 1983) ISSN: 0174-4879 [Print] Germany
• PMID: 6862719 (Publication Type: Journal Article)

Chemical References

• Aerosols
• Bronchodilator Agents
• Ethanolamines
• pirbuterol

Topics

• Adult
• Aerosols
• Aged
• Asthma (drug therapy, physiopathology)
• Bronchodilator Agents (administration & dosage, therapeutic use)
• Ethanolamines (administration & dosage, therapeutic use)
• Humans
• Lung (physiopathology)
• Middle Aged